Expert Review of Pharmacoeconomics & Outcomes Research

Article	Citations
Social care data in the UK; current landscape, challenges, and future recommendations	36
How to create value with constrained budgets in oncological care? A narrative review	23
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States	21
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment	19
Indication-based pricing of the pharmaceuticals in Croatia: case-study	18
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	18
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia	17
Adherence to augmentation therapy for the treatment of major depressive disorder	16
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis	13
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study	13
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency	12
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data	12
The role of insurance policies in the drug pricing landscape	12
A methodological guide for implementing and interpreting results of probabilistic analysis	11
Consumption of antidepressants and economic austerity in Brazil	11
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain	11
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer	11
The impact of bone turnover marker on medication adherence and the health economics-related consequences	9
Cost effectiveness of non-pharmacological interventions for fatigue in patients with long-term conditions: a systematic literature review	9
Burden of disease and costs of infections associated with cardiac implantable electronic devices	9
The impact of under-investment on health in Southern and Central Eastern European Countries	9
Mapping of the health of the Nation Outcomes Scale (HoNOS) and Positive and Negative Symptom Scale (PANSS) to the EQ-5D-3L in psychosis patients using the PHAMOUS study	9
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective	9
International comparability of reference unit costs of education services: when harmonizing methodology is not enough (PECUNIA project)	8
Regulatory perspectives on post-market evidence generation schemes for high-risk medical devices: a systematic review	8

Cost-utility analysis of multiple sclerosis rehabilitation in Iran	8
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States	8
Assessment of the properties of the EQ-5D-5L in patients with type 2 diabetes mellitus: a systematic review and meta-analysis	7
An update on the economic burden of type 2 diabetes mellitus in China	7
Burden of illness among intermittent catheter users with non-neurogenic urinary retention in Denmark	7
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system	7
Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis	7
Access to medicines, care, and services for multiple sclerosis patients in Central and Eastern European countries: a comparative analysis	7
Systematic reviews of machine learning in healthcare: a literature review	7
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis	7
Digital measures in epilepsy in low-resourced environments	7
Valuing quality of life for economic evaluations in cancer: navigating multiple methods	7
Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66–84 years in Japan and Shiga prefecture	7
Impact of patient’s financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes	7
Patients’ health related quality of life after massive weight loss reconstruction in the Netherlands	6
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma	6
Value elements and methods of value-based pricing for drugs in Japan: a systematic review	6
How relevant is the BMI for cost-of-illness studies in the 21st century?	6
Estimation of the economic burden of atrial fibrillation-related stroke in Greece	6
Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy	6
Cost–utility analysis of dupilumab compared with endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps. Evaluation in Colombia, a developing country	6
Adherence to oral anticoagulants in patients with non-valvular atrial fibrillation: the role of patients’ characteristics and out-of-pocket payments	6
The socioeconomic burden of cervical cancer and its implications for strategies required to achieve the WHO elimination targets	6
Valuing prevention: lessons and recommendations from a Dutch expert committee	6
Qualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countries	6
Prevalence and direct costs of potentially inappropriate prescriptions in France: a population-based study	6
Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation	6
Evaluation instruments for executive functions in children and adolescents: an update of a systematic review	6
Considering potential solutions for limitations and challenges in the health economic evaluation of gene therapies	6
Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics	6
Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve	6
Intravenous and subcutaneous vedolizumab for moderately to severely active ulcerative colitis in Iran: a model-based cost-effectiveness evaluation	6
Reimagining pharmacoeconomics in the age of artificial intelligence: opportunities, challenges, and future directions	5
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	5
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system	5
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening	5
Development and implementation of a stratified enhanced recovery after surgery pathway for ventral hernia repair	5
The substantial costs to society associated with obesity – a Danish register-based study based on 2002-2018 data	5
Bridging the gap: enhancing medication adherence through research and innovation	5
Burden of disease of chronic pain in Ecuador	5
Adherence to asthma and COPD inhaled therapies in low- and middle-income countries: a narrative review	5
Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies	5
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma	5
Transdisciplinary health economics for 2050: the challenge of preventing the adverse health effects of obesity, inequalities, and climate change	5
The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama	5
In-hospital economic burden of anastomotic leakage after colorectal anastomosis surgery: a real-world cost analysis in Italy	5
Precision medicine in Thoracic Oncology: understanding disparities to tackle inequities in access	5
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	5
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study	5
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe	5

Economic benefits of global Collaborative Health technology	5
Mapping the World Health Organization Disability Assessment Scale 2.0 to the EQ-5D-5L in patients with mental disorders	5
Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)	5
Developing the Lebanese health economic evaluation guideline	5
Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review	4
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 – 2020	4
The economic impact of pharmacist intervention during pandemics	4
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment	4
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia	4
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation	4
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy	4
The Lebanese health economic evaluation guideline	4
Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines – a case study of oncology drugs	4
The Economics of prevention and quality of care: policy insights from the EU’s COVID-19 response	4
The hidden burden of atopic dermatitis in central and Eastern European countries	4
Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial	4
Analysis of patients’ access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece	4
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data	4
Enhancing pharmacist intervention targeting based on patient clustering with unsupervised machine learning	4
Psychometric properties of outcome measures for freezing of gait in Parkinson’s disease: a systematic review and meta-analysis	4
Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC)	4
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions	4
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review	4
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer	4
Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population	4
Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment	4
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review	4
Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective	3
How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015–2021	3
Exploring the approach to parameter uncertainty in early economic evaluations of surgical technology – a systematic review	3
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective	3
Assessing the impact of kidney cancer-related premature mortality and productivity loss in Greece and Portugal	3
Public value judgments about the criteria for reimbursement of medicines in South Korea	3
What are the costs of managing neck and low back pain in Brazil? Investigation of a ten-year period from the perspective of the Brazilian public health system	3
Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model	3
Can artificial intelligence separate the wheat from the chaff in systematic reviews of health economic articles?	3
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece	3
Evaluating reporting of patient-reported outcomes in peptic ulcer disease: a meta-epidemiological study of randomized controlled trials	3
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China	3
Burden of disease of chronic pain in Colombia	3
Systematic review of the impact of health care expenditure on health outcome measures: implications for cost-effectiveness thresholds	3
The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey	3
Normative data and socio-demographic determinants of the dermatology life quality index in a large online sample of the Hungarian population	3
Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves	3
Correction	3
Perspectives in prospective comparative economic evaluations: a systematic review	3
Assessment of Quality of Life 8-Dimension (AQoL-8D): translation, validation, and application in two Dutch trials in patients with epilepsy and schizophrenia	3
Cost and health impact analysis of herpes zoster vaccination in Norway	3
Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell, or solid organ transplantation – a perspective of the German healthcare system	3
Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective	3
Implementing a Managed Entry Agreement Framework in Cyprus	3
The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China	3
Design and testing of a health economic Markov model for treatment of anorexia nervosa	3
Barriers to digital endpoints in data collection in low and middle-income countries	3
Patient-relevance of outcome measures in breast cancer clinical trials: a cross-sectional comparative analysis of patient preferences and trials conducted between 2014 and 2024	3
Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare	3
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program	3
Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China	3
The short-term impact of copayment reductions for government subsidised medicines in Australia	3
System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model	3
Perceptions of risk sharing agreements in South Korea from the viewpoints of key stakeholders: a convergent parallel mixed approach	3
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective	3
A roadmap for applying machine learning when working with privacy-sensitive data: predicting non-response to treatment for eating disorders	3
Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview	3
Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece	3
Economic burden of suicides and suicide attempts in low- and middle-income countries: a systematic review of costing studies	2
What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States	2
Is the shift in treatment patterns towards new, more expensive drugs still driving the increase in pharmaceutical expenditure? A decomposition analysis of expenditure data in Sweden 1990–2022	2
Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia	2
Budget impact of low-dose computed tomography screening for lung cancer in Argentina	2
Effects of utilization management on health outcomes: evidence from urinary tract infections and community-acquired pneumonia	2
Health-related quality of life in women with autoimmune thyroid disease during pregnancy and postpartum: systematic review including 321,850 pregnancies	2
Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program	2
Analysis of prescriptive monitoring regarding the current therapeutic landscape of rheumatoid arthritis: the experience of an Italian local health authority	2
Hospital incidence and costs of congenital hydrocephalus in Spain: a multicenter retrospective study	2
The impact of non-pharmacological interventions on adherence to medication and persistence in dyslipidaemia and hypertension: a systematic review	2
The utility and impact of digital endpoints for improving breast cancer outcomes	2
How can patients shape digital medicine? A rapid review of patient and public involvement and engagement in the development of digital health technologies for neurological conditions	2
Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health	2
Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US	2

Risk prediction algorithms in guiding antiviral therapy initiation among patients with chronic hepatitis B in Thailand: an economic evaluation and budget impact analysis	2
Correction	2
The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran	2
Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial	2
Proposed method for economic evaluation based on basket trials: a case study of pembrolizumab	2
Pharmacovigilance and outcomes: experience from Saudi Arabia narrative review	2
Emerging trends: the involvement of community pharmacists in the planning and execution of pharmaceutical policies and economics	2
Integrated care in Western Europe: a wise solution for the future?	2
A pre-vaccine analysis using the Health Belief Model to explain parents’ willingness to vaccinate (WTV) their children in the United States: implications for vaccination programs	2
The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention	2
The cost-of-illness of multiple sclerosis in Jordan	2
A review of caregiver costs included in cost-of-illness studies	2
Direct healthcare costs for people with cerebral palsy in the Brazilian unified health system between 2015 and 2019	2
A landscape analysis and discussion of value of gene therapies for sickle cell disease	2
Prescription drug coverage satisfaction and medication nonadherence among Medicare beneficiaries with cancer	2
Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China	2
Budget impact analysis of daratumumab for light-chain amyloidosis in Cyprus	2
Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China	2
The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients	2
Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia	2
Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: a governance analysis	2
Willingness to pay for a quality-adjusted life year (QALY) in Pakistan: implications for health policy	2
Financial evaluation of value-creating biosimilar development candidates: a business case study of low-, medium- and high-sales biosimilars	2
The Economic and societal burden of multiple sclerosis on lebanese society: a cost-of-illness and quality of life study protocol	2
What to expect in 2024: important health economics and outcomes research (HEOR) trends	2
Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Sing	2
Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina	2
Work productivity in rheumatoid arthritis patients from two Latin American countries treated with tofacitinib or biological DMARDs	2
How unprofessional behaviours between healthcare staff threaten patient care and safety	2
The cost-effectiveness of using rapid diagnostic tests for the diagnosis of typhoid fever in patients with suspected typhoid fever: a systematic review	2
Analysis of the prevalence of ankylosing spondylitis and treatment patterns and drug utilization among affected patients: an Italian real-world study	1
A retrospective budget impact analysis of fidaxomicin treatment for Clostridioides difficile infections (CDI) in Germany	1
All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain	1
Challenges in resource allocation of diagnostic tests in Spain	1
Challenges with integrating early-stage cancer trial endpoints into economic models: review of health technology recommendations for adjuvant or neoadjuvant therapies in Canada	1
Cost-utility analysis of duloxetine in osteoarthritis: from Chinese healthcare perspective	1
Content and cost of waste pharmaceuticals collected by pharmacies for disposal	1
A perspective on the use of patient-reported experience and patient-reported outcome measures in ambulatory healthcare	1
Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update	1
Nonadherence to antiseizure medications: what have we learned and what can be done next?	1
Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023	1
Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies	1
Matching-adjusted indirect comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-cell lymphoma in China	1
The budget impact of introducing the OMNI® surgical system to a United States health plan for managing mild-to-moderate primary open-angle glaucoma	1
Fiscal analysis of the pediatric immunization program in Belgium applying a lifetime government perspective framework	1
Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada	1
Multicenter, cross-sectional study of the economic burden of multiple sclerosis and cost-driving factors	1
Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer	1
Preference of young adults for COVID-19 vaccination in the United Kingdom: a discrete choice experiment	1
Cost-effectiveness analysis of 20-valent anti-pneumococcal vaccination in the Spanish pediatric population	1
Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder	1
Evaluating high-cost technologies – no need to throw the baby out with the bathwater	1
Patient preferences in chronic immune-mediated inflammatory diseases potentially treated with biological drugs: discrete choice analysis using real-world data analysis	1
First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis	1
Understanding the upper bound of survival for conducting and critically appraising economic evaluations of low-risk cancers	1
Clinical and economic outcomes of patients with cardiorenal and metabolic diseases: a real-world analysis in a single Italian Local Health Unit	1
Multicriteria decision analysis in health care decision in oncology: a systematic review	1
Moving towards a more environmentally sustainable pharmaceutical industry: recommendations for industry and the transition to green HTA	1
Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore	1
Incorporating public and wider stakeholder views in the design of health state valuation studies in adults and young people: an undervalued resource?	1
Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension	1
Economic evaluation of interventions to improve medication adherence among patients with chronic diseases: an overview of systematic reviews	1
Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies — can alignment be improved?	1
Economic evaluation of stereotactic radiotherapy and stereotactic radiosurgery technologies in the treatment of cancers: a systematic review	1
Review of economic modeling evidence from NICE appraisals of rare disease treatments for spinal muscular atrophy	1
Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?	1
Letter to the editor regarding “Budget impact analysis of pneumococcal conjugate vaccines in Colombia”	1
Tackling reimbursement challenges to fair access to medicines – introduction to the topic	1
The economic benefits of fracture prevention	1
HTA challenges for appraising rare disease interventions viewed through the lens of an institutional multidimensional value framework	1
The evolution and future of integrated evidence planning	1
Leveraging sensor-based functional outcomes to enhance understanding of the patient experience: challenges and opportunities	1
A review of methodological aspects of economic evaluations used in NICE assessments for treatments in metastatic breast cancer	1
Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma	1
Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China	1
Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China	1
Robot-assisted medication management in home care and long-term care settings: a mixed-Method systematic review	1
A scoping review on patient heterogeneity in economic evaluations of precision medicine based on basket trials	1
Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study	1
An early economic analysis of medical cannabis for the treatment of chronic pain	1
Assessing smoking cessation services and pharmacotherapy in Namibia: findings and implications for future policy initiatives	1
Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia	1
The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer	1
Natural language processing – relevance to patient outcomes and real-world evidence	1
Cost of illness in multiple sclerosis by disease characteristics – A review of reviews	1
Burden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care	1
Cost-consequence analysis of diagnosis and early treatment of acquired thrombotic thrombocytopenic purpura in Colombia	1
Prescription analysis and cost of antidepressant drugs in major depressive disorder outpatients at the tertiary care hospital of Pakistan: a prospective approach	1
An exploratory cost-effectiveness analysis of a novel tissue valve compared with mechanical valves for surgical aortic valve replacement in subgroups of people aged 55–64 and 65+ with aortic stenosis	1
Cost-benefit analysis of hepatic resection, radiofrequency ablation and liver transplantation in small hepatocellular carcinoma	1
The clinical and economic burden of illness in the first two years after ostomy creation: a nationwide Danish cohort study	1
Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor	1
Autologous stem-cell transplantation and maintenance therapy for transplant-eligible multiple myeloma patients: cost-effectiveness analysis based on a network meta-analysis	1
Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspe	1
Estimated value of productivity lost due to childhood chickenpox in the United Kingdom: a survey of parents	1